Background: Recently, it has been shown that the polymorphism 385 C/A of FAAH (fatty acid amide hydrolase) was associated with overweight and obesity. Visfatin has been identified as a protein expressed in visceral adipose tissue with contradictory functions in glucose metabolism. Objective: The aim of our study was to investigate the relationship between polymorphism (cDNA 385 C-4A) of the FAAH gene and visfatin levels in obese women. Design: A population of 143 females with obesity was analyzed. Indirect calorimetry, tetrapolar electrical bioimpedance, blood pressure and serial assessment of nutritional intake with 3-day written food records and biochemical analysis (lipid profile, visfatin, insulin, C-reactive protein and homeostasis model assessment for insulin sensitivity (HOMA)) were performed. Results: Ninety-four patients (65.7%) had the genotype C358C (wild-type group) and 49 (34.3%) patients had the genotype C358A (mutant type group). No differences were detected between groups in anthropometric parameters and dietary intakes. Insulin (15.6±7.6 vs 14.1±10.1 mUI l À1 ; Po0.05), glucose (101.2±21.9 vs 92.3±10.5 mg per 100 ml; Po0.05) and HOMA values (3.96 ± 2.3 vs 3.15 ± 2.8; Po0.05) were higher in the wild type-group than in the mutant type group. Visfatin levels were lower in the wild-type group than in the mutant type group (47.83±57.5 vs 65.71±55 ng ml À1 ; Po0.05).
Introduction
Visfatin has been identified as a protein preferentially expressed in visceral adipose tissue, compared with subcutaneous adipose tissue. Fukuhara et al. 1 clearly suggested an endocrine role for visfatin, and it cannot be excluded that visfatin might also have a paracrine effect on the visceral adipose tissue through its pro-adipogenic and lipogenic actions. Contrary to the most intuitive hypothesis, visfatin treatment did not promote insulin resistance, but actually exhibited insulin mimetic properties resulting in a glucoselowering effect. 2 Also, it is known that serum visfatin concentrations may be correlated with body weight in healthy subjects. Changes in dietary intake such as underfeeding, overfeeding and exercise have important effects on adipose tissue metabolism 3, 4 and may affect visfatin concentrations
The current view of adipose tissue is that of an active secretory organ, sending out and responding to signals that modulate appetite, insulin sensitivity and energy expenditure. 5 The endocannabinoid system is also related to fat tissue. 6 The endogenous cannabinoid system mediates its position both functionally and anatomically 7 to act as an important modulator of normal human brain behavior. The main inactivating enzyme of endogenous cannabinoid receptor ligands is fatty acid amide hydrolase (FAAH), which has been identified as the catabolic enzyme capable of inactivating most of the endocannabinoids. 3 A polymorphism (cDNA 385 C-4A) that predicts a substitution of threonine for a conserved proline residue at amino acid position 129 (P129T) has been described and is significantly associated with drug abuse. 8 Sipe et al. 9 have shown that the homozygous FAAH 385 A/A genotype was associated with overweight and obesity. Monteleone et al. 10 confirmed previously published significant overrepresentations of the FAAH 385A allele in overweight/obese subjects. Considering the evidence that the endogenous cannabinoid system has a role in metabolic aspects of body weight, 11 the aim of our study was to investigate the relationship between the polymorphism (cDNA 385 C-4A) of the FAAH gene and visfatin levels in obese women. The aim of our study was to investigate the relationship between the polymorphism (cDNA 385 C-4A) of the FAAH gene and visfatin levels in obese women.
Subjects and methods

Subjects
A population of 143 Caucasian females with obesity (body mass index, BMI430) was analyzed in a prospective way. These patients were recruited in a Nutrition Clinic Unit and signed an informed consent. Exclusion criteria included total cholesterol 4300 mg per 100 ml, triglycerides 4400 mg per 100 ml, blood pressure 4140/90 mm Hg, fasting plasma glucose 4126 mg per 100 ml. The local ethics committee approved the protocol.
Procedure
Weight, blood pressure, basal glucose, C-reactive protein, insulin, insulin resistance (HOMA), total cholesterol, lowdensity lipoprotein-cholesterol, high-density lipoproteincholesterol, triglyceride blood and visfatin levels were measured at basal time. A tetrapolar bioimpedance, an indirect calorimetry and a prospective serial assessment of nutritional intake with 3-day written food records were realized. The genotype of the FAAH gene polymorphism was studied.
Assays
Plasma glucose levels were determined by using an automated glucose oxidase method (Glucose analyzer 2, Beckman Instruments, Fullerton, CA, USA). Insulin was measured by RIA (RIA Diagnostic Corporation, Los Angeles, CA, USA) with a sensitivity of 0.5 mUI l À1 (normal range 0.5-30 mUI l À1 ) 12 and the homeostasis model assessment for insulin sensitivity (HOMA) was calculated using these values. 13 C-reactive protein was measured by immunoturbimetry (Roche Diagnostics GmbH, Mannheim, Germany), with a normal range of 0-7 mg per 100 ml and analytical sensivity of 0.5 mg per 100 ml. Serum total cholesterol and triglyceride concentrations were determined by enzymatic colorimetric assay (Technicon Instruments Ltd., New York, NY, USA), whereas high-density lipoprotein cholesterol was determined enzymatically in the supernatant after precipitation of other lipoproteins with dextran sulfate magnesium. Low-density lipoprotein cholesterol was calculated using the Friedewald formula. 14 Visfatin was analyzed using a commercially available ELISA kit (Phoenix Peptides, Belmont, CA, USA). Assay sensitivity was 2 ng ml À1 and interassay and intra-assay coefficients of variation were less than 10 and 5%, respectively.
Genotyping of FAAH gene polymorphism
Oligonucleotide primers and probes were designed with the Beacon Designer 4.0 (Premier Biosoft International, LA, CA, USA). The PCR was carried out with 50 ng of genomic DNA, 0.5 ml of each oligonucleotide primer (primer forward, 5 0 -CTATCTGGCTGACTGTGAGACTC-3 0 ; primer reverse, 5 0 -GAGGCAGAGCATACCTTGTAGG-3), and 0.25 ml of each of the probes ((wild probe: 5 0 -Fam-CTGTCTCAGGCCCC AAGGCAGG-BHQ-1-3 0 ) and (mutant probe: 5 0 -Hex-CTGTC TCAGGCCACAAGGCAGG-BHQ-1-3 0 )) in a 25 ml final volume (Termociclador iCycler IQ (Bio-Rad), Hercules, CA, USA). DNA was denaturated at 95 1C for 3 min; this was followed by 50 cycles of denaturation at 95 1C for 15 s, and annealing at 59.3 1 for 45 s). The PCR were run in a 25 ml final volume containing 12.5 ml of IQTM Supermix (Bio-Rad) with hot start Taq DNA polymerase. The Hardy-Weinberg equilibrium was assessed.
Nutritional evaluation Indirect calorimetry. For the measurement of resting energy expenditure, subjects were admitted to a metabolic ward. After a 12 h overnight fast, the resting metabolic rate was measured in the sitting awake subject in a temperaturecontrolled room over one 20 min period with an open-circuit indirect calorimetry system (standardized for temperature, pressure and moisture) fitted with a face mask (MedGem; Health Tech, Golden, CO, USA) having a coefficient of variation of 5%. Resting metabolic rate (kcal day À1 ) and oxygen consumption (ml min À1 ) were calculated. 15 Anthropometric measurements Waist (narrowest diameter between xiphoid process and iliac crest) and hip (widest diameter over greater trochanters) circumferences to derive waist-to-hip ratio were measured, too. Tetrapolar body electrical bioimpedance was used to determine body composition with an accuracy of 5 g (Biodynamics Model 310e, Seattle, WA, USA). 16 Body weight was measured to an accuracy of 0.1 kg and BMI was computed as body weight/(height 2 ). Blood pressure was measured twice after a 10 min rest with a random zero mercury sphygmomanometer, and averaged.
Dietary intake and habits
Patients received prospective serial assessment of nutritional intake with 3-day written food records. All enrolled subjects 
Results
One hundred forty-three patients gave informed consent and were enrolled in the study. The mean age was 44.9 ± 11 years and the mean BMI 34.9±5.1. All subjects were weight stable during the 2-week period preceding the study (body weight change, 0.21 ± 0.1 kg). Ninety-four patients (65.7%) had the genotype C358C (wild-type group) and 49 (34.3%) patients had the genotype C358A (mutant type group). Genotype (A358A) was not detected in our sample. Age was similar in both groups (wildtype group: 44.82±15.9 years vs mutant group: 45.1±16.4 years, nonsignificant). Table 1 shows the anthropometric variables. No differences were detected between the groups. Table 2 shows the metabolic variables. Glucose, insulin and HOMA values were higher in the wild-type group than in the mutant type group. Visfatin levels were lower in the wild-type group than in the mutant type group (47.83 ± 57.5 vs 65.71 ± 55 ng ml À1 ; Po0.05). Table 3 shows nutritional intake with 3-day written food records. No statistical differences were detected in caloric, carbohydrate, fat and protein intakes. Aerobic exercise per week was similar in both groups.
Correlation analysis between visfatin and other anthropometric and biochemical parameters show a negative correlation with weight (r ¼ À0.14; Po0.05), BMI (r ¼ À0.13; P ¼ 0.05), fat mass (r ¼ À0.11; Po0.05), insulin (r ¼ À0.10; P ¼ 0.05) and HOMA (r ¼ À0,10; P ¼ 0.05).
After univariate analysis, we performed a multivariate analysis. In this analysis, adjusted by age with a dependent variable (visfastin), the C/A358 remained in the model (F ¼ 1.32; Po0.05), with an increase of 11.7 (confidence interval 95%: 2.1-25.4) ng ml À1 with the presence of the A allele. Fatty acid amide hydrolase and visfatin DA de Luis et al
Discussion
As genetic influences are thought to have a greater role in obesity, identification of the obesity polymorphism may be an interesting area of clinical investigation. A C358A singlenucleotide polymorphism of FAAH results in a missense mutation producing FAAH with defective expression 18 . In our study, the percentage of AC genotype (34.3%) was similar to that of other studies: 28.1 10 , 24.1 19 and 36.5%.
11
In our design, we investigated the effect of FAAH genetic variation on visfatin levels. The novel finding of this study is the association of the C358C FAAH genotypes with lower levels of visfatin and higher levels of glucose, HOMA and insulin than of the C358A FAAH genotype, without differences in anthropometric parameters related to obesity. 19 A previous association between this polymorphism and metabolic profile has been described. Interestingly, Aberle et al. 20 have shown that carriers of the A allele had a significantly greater decrease in the total cholesterol and triglycerides compared with wild type when following a low-fat diet.
We can speculate that the effects of FAAH A385A on visfatin and glucose metabolism could be secondary to the upregulation of natural reward behaviors such as consumption of sweets and palatable food associated with overweight and obesity. The mesolimbic addition and reward/craving circuit including the medial forebrain bundle projections to the nucleus accumbens shows a high correlation between FAAH enzyme expression and CB1 receptor density. 21 However, our design controlled dietary intake, and neither caloric intake nor macronutrient distribution was different between both genotypes.
Accumulating evidence indicates that the endogenous cannabinoid system is an essential homeostatic regulator of energy balance and weight. 22 Patients with C358A FAAH polymorphism have half the FAAH enzymatic activity and protein expression compared with wild-type subjects. 18 This provide a link between the consequences of this polymorphism and the present epidemiological study indicating that the FAAH A358A polymorphism may have a role in decreased or increased metabolic risk associated with obesity. In our study, the high glucose, insulin and HOMA levels and low visfatin levels in patients with wild-type genotype could be related to an altered postprandial response of fatty acids absorption (not measured in our design). The lack of association of this biochemical modifcaction with fat mass or BMI could indicate the existence of complex unmeasured gene-gene or gene-environment interactions that may enhance metabolic abnormalities in obese patients. Other hypotheses to explain this better metabolic profile of mutant type patients could be secondary to high levels of visfatin. The relation among visfatin levels and biochemical and anthropometric parameters are an unclear area. For example, mRNA expression and circulating levels of visfatin were increased in the diabetic versus nondiabetic patients. 1 One reason for these data is the high body weight in diabetic patients. However, another study, using waist circumference as a marker for visceral fat, showed no significant correlation with circulating visfatin. 23 It is necessary to determine the contribution of visfatin originating from visceral adipose tissue to the control of global insulin sensitivity. Although the affinity of visfatin for the insulin receptors appears to be similar to insulin, its concentration in plasma is much lower than the insulin concentration under fasting conditions. 24 It remains to be established whether visfatin production is a compensatory response to tissue-specific insulin resistance or more simply a marker of tissue-specific inflammatory cytokine action. Perhaps a new hypothesis could explain the contradictory results of the literature. Haider et al. 25 have detected that the release of visfatin by adipocytes was dependent on the duration and magnitude of glucose elevations; these data suggest that visfatin release may represent a nutrient sensor of adipocytes and fail to detect a relationship between some parameters of metabolic syndrome and visfatin. An interesting hypothesis to explain our results is the hypothetical direct interaction between the cannabinoid system and the expression of visfatin by fat tissue. 26 However, this is an area with little evidences. In the literature, an increase of visfatin levels in obesity was related to preservation of insulin sensitivity; it enhances glucose uptake by adipocytes and inhibits hepatocyte glucose release. In humans, visfatin concentrations are influenced by glucose or insulin blood levels. 25 Furthermore, the fact that visfatin increases in plasma following a high-fat diet suggests that it has an important role in diet-or obesityinduced insulin resistance. 24 A significant positive correlation was found between visfatin and circulating markers of inflammation such as C-reactive protein, suggesting a possible role of visfatin in the cardiovascular system. 27 In conclusion, the novel finding of this study is the association of the mutant type group A358C of FAAH with a better metabolic profile (insulin, glucose, visfatin and HOMA levels) than of the wild-type group. Further studies are needed to elucidate this complex relationship in an independent way of BMI.
